Chemomab Therapeutics Ltd. Holds Special Shareholder Meeting

TL;DR

CHEMO held a shareholder meeting Nov 18, 2024. Details to follow.

AI Summary

Chemomab Therapeutics Ltd. held a special general shareholders meeting on November 18, 2024, to discuss and vote on certain matters. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is a pharmaceutical preparations company incorporated in Israel.

Why It Matters

This filing indicates corporate governance activities and shareholder engagement for Chemomab Therapeutics Ltd., which is relevant for investors tracking the company's operational and strategic decisions.

Risk Assessment

Risk Level: low — This filing is a routine report of a shareholder meeting and does not contain new financial or operational information that would significantly alter risk.

Key Players & Entities

• Chemomab Therapeutics Ltd. (company) — Registrant
• Anchiano Therapeutics Ltd. (company) — Former Company Name
• BioCancell Ltd. (company) — Former Company Name
• November 18, 2024 (date) — Date of Shareholder Meeting

FAQ

Filing Documents

• zk2432350.htm (6-K) — 10KB
• 0001178913-24-003747.txt ( ) — 11KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant's name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE Chemomab Therapeutics Ltd. (the "Company") hereby furnishes the results of a special general shareholders meeting (the "Meeting"), which was held on November 18, 2024, at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. At the Meeting, the Company's shareholders voted upon and approved, by the requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association (the "Articles"), the following proposal: to approve a grant of 126,848 restricted share units (RSUs) to Dr. Adi Mor, the Company's Chief Executive Officer, Chief Scientific Officer and member of the board of directors. All in accordance with the Company's proxy statement related to the Meeting, which was attached as Exhibit 99.1 to the Company's Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on October 11, 2024. This Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-281750 and No. 333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: November 18, 2024 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR